Study of chemotherapy side effects in older colorectal cancer patients
Part of Brain & nervous system, Cancer, Digestive system clinical trials.
This study looks at how chemotherapy and immunotherapy affect the body in older adults with colorectal cancer, especially early side effects. It may help researchers understand why some people lose strength and how to better predict and manage treatment toxicity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that is metastatic (or it came back in a metastatic way).
- Your metastatic cancer diagnosis/return happened at least 3 months after finishing treatment for non-metastatic colorectal cancer.
- You are starting or planning to get first-line immunotherapy and/or chemotherapy that contains 5-FU (with or without oxaliplatin and/or irinotecan, and capecitabine is also allowed).
- Your estimated life expectancy is at least 6 months.
- You can read and understand English or Spanish, and you can sign consent.
- You are not on hospice, not getting other experimental study drugs, and you do not have untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how muscle loss (sarcopenia) might affect side effects from cancer treatments. If you are starting a new cancer treatment, a CT scan before treatment can help doctors predict your risk of side effects.
This trial looks at muscle loss (called sarcopenia) in people with colon cancer to test an intervention that may help strength or recovery. If you’re age 70 or older and meet the cancer and health requirements, you may be able to take part.
This trial tests two chemotherapy drugs, capecitabine alone or with oxaliplatin, in people aged 70 or older after surgery for stage III colorectal cancer. The goal is to find out which treatment works better to prevent cancer from coming back.
This trial looks at sarcopenia (loss of muscle strength/size) and vertigo (feeling dizzy or off-balance) in older adults with colorectal cancer. It tests whether a structured, exercise-based approach can help these issues alongside cancer care.
This study looks at how muscle loss (sarcopenia) affects people diagnosed with colorectal cancer before age 50. It uses CT or MRI scans taken at diagnosis to measure muscle mass and see how it relates to treatment and outcomes.
This study looks at how common muscle weakness (sarcopenia) and thinking or memory changes (often called “chemobrain”) are in people after cancer treatment. It may help teams understand what support could be most helpful after chemotherapy.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.